Top

Published in:

Open Access 01-02-2022 | Brachytherapy | Review Article

The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry

Authors: Tibor Major, Georgina Fröhlich, Péter Ágoston, Csaba Polgár, Zoltán Takácsi-Nagy

Published in: Strahlentherapie und Onkologie | Issue 2/2022

Abstract

Brachytherapy (BT) has long been used for successful treatment of various tumour entities, including prostate, breast and gynaecological cancer. However, particularly due to advances in modern external beam techniques such as intensity-modulated radiotherapy (IMRT), volume modulated arc therapy (VMAT) and stereotactic body radiotherapy (SBRT), there are concerns about its future. Based on a comprehensive literature review, this article aims to summarize the role of BT in cancer treatment and highlight its particular dosimetric advantages. The authors conclude that image-guided BT supported by inverse dose planning will successfully compete with high-tech EBRT in the future and continue to serve as a valuable modality for cancer treatment.

Guedea F, Venselaar J, Hoskin P, Hellebust TP, Peiffert D, Londres B et al (2010) Patterns of care for brachytherapy in Europe: updated results. Radiother Oncol 97:514–520. https://doi.org/10.1016/j.radonc.2010.09.009CrossRefPubMed

Gill BS, Lin JF, Krivak TC, Sukumvanich P, Laskey RA, Ross MS, Lesnock JL, Beriwal S (2014) National cancer data base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. Int J Radiat Oncol Biol Phys 90:1083–1090. https://doi.org/10.1016/j.ijrobp.2014.07.017CrossRefPubMed

Petereit DG, Frank SJ, Viswanathan AN, Erickson B, Eifel P, Nguyen PL et al (2015) Brachytherapy: where has it gone? J Clin Oncol 33:980–982. https://doi.org/10.1200/JCO.2014.59.8128CrossRefPubMedPubMedCentral

Shah C, Lanni TB Jr, Ghilezan MI, Gustafson GS, Marvin KS, Ye H et al (2012) Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy 11:441–445. https://doi.org/10.1016/j.brachy.2012.04.002CrossRefPubMed

Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN (2013) Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys 87:111–119. https://doi.org/10.1016/j.ijrobp.2013.05.033CrossRefPubMed

Mahmood U, Pugh T, Frank S, Levy L, Walker G, Haque W et al (2014) Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy 13:157–162. https://doi.org/10.1016/j.brachy.2013.08.005CrossRefPubMed

Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM et al (2014) The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the national cancer data base. Cancer 120:2114–2121. https://doi.org/10.1002/cncr.28697CrossRefPubMed

Vu CC, Jawad MS, Krauss DJ (2019) The cost-effectiveness and value proposition of brachytherapy. Semin Radiat Oncol 30:87–93. https://doi.org/10.1016/j.semradonc.2019.08.007CrossRef

Safdieh J, Wong A, Weiner JP, Schwartz D, Schreiber D (2016) Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated? J Contemp Brachytherapy 8:289–293. https://doi.org/10.5114/jcb.2016.61942CrossRefPubMedPubMedCentral

10.

Glaser SM, Dohopolski MJ, Balasubramani GK, Benoit RM, Smith RP, Beriwal S (2017) Brachytherapy boost for prostate cancer: trends in care and survival outcomes. Brachytherapy 16:330–341. https://doi.org/10.1016/j.brachy.2016.12.015CrossRefPubMed

11.

Corkum MT, Morton G, Louie AV, Bauman GS, Mendez LC, Chin J et al (2020) Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada. Radiother Oncol 152:42–48. https://doi.org/10.1016/j.radonc.2020.07.036CrossRefPubMed

12.

Tanderup K, Eifel PJ, Yashar CM, Pötter R, Grigsby PW (2014) Curative radiation therapy for locally advanced cervical cancer: brachytherapy is NOT optional. Int J Radiat Oncol Biol Phys 88:537–539. https://doi.org/10.1016/j.ijrobp.2013.11.011CrossRefPubMed

13.

Holschneider CH, Petereit DG, Chu C, Hsu IC, Ioffe YJ, Klopp AH et al (2019) Brachytherapy: a critical component of primary radiation therapy for cervical cancer: from the society of gynecologic oncology (SGO) and the American brachytherapy society (ABS). Gynecol Oncol 152:540–547. https://doi.org/10.1016/j.ygyno.2018.10.016CrossRefPubMed

14.

NCCN (2019) NCCN guidelines version 4.2019 cervical cancer. https://www2.tri-kobe.org/nccn/guideline/gynecological/english/cervical.pdf. Accessed 20 May 2021

15.

Kirisits C, Schmid MP, Beriwal S, Pötter R (2015) High-tech image-guided therapy versus low-tech, simple, cheap gynecologic brachytherapy. Brachytherapy 14:910–912. https://doi.org/10.1016/j.brachy.2015.08.010CrossRefPubMed

16.

Milickovic N, Tselis N, Karagiannis E, Ferentinos K, Zamboglou N (2017) Iridium-knife: another knife in radiation oncology. Brachytherapy 16:884–892. https://doi.org/10.1016/j.brachy.2017.03.005CrossRefPubMed

17.

Patel RR, Becker SJ, Das RK, Mackie TR (2007) A dosimetric comparison of accelerated partial breast irradiation techniques: multicatheter interstitial brachytherapy, three-dimensional conformal radiotherapy, and supine versus prone helical tomotherapy. Int J Radiat Oncol Biol Phys 68:935–942. https://doi.org/10.1016/j.ijrobp.2007.03.005CrossRefPubMed

18.

Charaghvandi RK, den Hartogh MD, van Ommen ALN et al (2015) MRI-guided single fraction ablative radiotherapy for early-stage breast cancer: a brachytherapy versus volumetric modulated arc therapy dosimetry study. Radiother Oncol 117:477–482. https://doi.org/10.1016/j.radonc.2015.09.023CrossRefPubMed

19.

Terheyden MM, Melchert C, Kovács G (2016) External beam boost versus interstitial high-dose-rate brachytherapy boost in the adjuvant radiotherapy following breast-conserving therapy in early-stage breast cancer: a dosimetric comparison. J Contemp Brachytherapy 8:294–300. https://doi.org/10.5114/jcb.2016.61973CrossRefPubMedPubMedCentral

20.

Major T, Stelczer G, Pesznyák C, Mészáros N, Polgár C (2017) Multicatheter interstitial brachytherapy versus intensity modulated external beam therapy for accelerated partial breast irradiation: a comparative treatment planning study with respect to dosimetry of organs at risk. Radiother Oncol 122:17–23. https://doi.org/10.1016/j.radonc.2016.08.003CrossRefPubMed

21.

Shahbazian H, Bakhshali R, Shamsi A, Bagheri A (2020) Dosimetric analysis of breast cancer tumor bed boost: an interstitial brachytherapy vs. external beam radiation therapy comparison for deeply seated tumors. Brachytherapy 19:264–274. https://doi.org/10.1016/j.brachy.2019.10.008CrossRefPubMed

22.

Fröhlich G, Mészáros N, Smanykó V, Stelczer G, Herein A, Polgár C, Major T (2021) Is stereotactic CyberKnife radiotherapy or multicatheter HDR brachytherapy the better option in accelerated partial breast irradiation? Brachytherapy 20:326–331. https://doi.org/10.1016/j.brachy.2020.10.003CrossRefPubMed

23.

Herein A, Stelczer G, Pesznyák C, Fröhlich G, Smanykó V, Mészáros N, Polgár C, Major T (2021) Multicatheter interstitial brachytherapy versus stereotactic radiotherapy with CyberKnife for accelerated partial breast irradiation: a comparative treatment planning study with respect to dosimetry of organs at risk. Radiol Oncol. https://doi.org/10.2478/raon-2021-0016CrossRefPubMedPubMedCentral

24.

Periasamy K, Karunanithi G, Cholayil S, Dharanipragada K, Neelakanadan V (2021) Dosimetric comparison between interstitial brachytherapy and volumetric-modulated arc therapy for tumor bed boost in breast cancer. J Contemp Brachytherapy 13(3):302–309. https://doi.org/10.5114/jcb.2021.106141CrossRefPubMedPubMedCentral

25.

Georg D, Kirisits C, Hillbrand M, Dimopoulos J, Pötter R et al (2008) Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy. Int J Radiat Oncol Biol Phys 71:1272–1278. https://doi.org/10.1016/j.ijrobp.2008.03.032CrossRefPubMed

26.

Shwetha B, Ravikumar M, Palled SR, Supe SS, Sathiyan S (2011) Dosimetric comparison of high dose rate brachytherapy and intensity-modulated radiation therapy for cervical carcinoma. J Med Phys 36:111–116. https://doi.org/10.4103/0971-6203.79687CrossRefPubMedPubMedCentral

27.

Gielda BT, Shah AP, Marsh JC, Smart JP, Bernard D, Rotmensch J et al (2011) Helical tomotherapy delivery of an IMRT boost in lieu of interstitial brachytherapy in the setting of gynecologic malignancy: feasibility and dosimetric comparison. Med Dosim 36:206–212. https://doi.org/10.1016/j.meddos.2010.03.005CrossRefPubMed

28.

Sharma DN, Gandhi AK, Sharma S, Rath GK, Jagadesan P, Julka PK (2013) Interstitial brachytherapy vs. intensity-modulated radiation therapy for patients with cervical carcinoma not suitable for intracavitary radiation therapy. Brachytherapy 12:311–316. https://doi.org/10.1016/j.brachy.2012.10.003CrossRefPubMed

29.

Cengiz M, Dogan A, Ozyigit G, Erturk E, Yildiz F et al (2012) Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer. Brachytherapy 11:125–129. https://doi.org/10.1016/j.brachy.2011.12.001CrossRefPubMed

30.

Neumann O, Kluge A, Lyubina O, Wlodarczyk W, Jahn U, Köhler C (2014) Robotic radiosurgery as an alternative to brachytherapy for cervical cancer patients. Strahlenther Onkol 190:538–545. https://doi.org/10.1007/s00066-014-0614-4CrossRefPubMed

31.

Khosla D, Patel FD, Oinam AS, Tomar P, Sharma SC (2014) Dosimetric comparison of vaginal vault ovoid brachytherapy versus intensity-modulated radiation therapy plans in postoperative patients of cervical carcinoma following whole pelvic radiotherapy. J Cancer Res Ther 10:153–158. https://doi.org/10.4103/0973-1482.131449CrossRefPubMed

32.

Otahal B, Dolezel M, Cvek J, Simetka O, Klat J, Knybel L et al (2014) Dosimetric comparison of MRI-based HDR brachytherapy and stereotactic radiotherapy in patients with advanced cervical cancer: a virtual brachytherapy study. Rep Pract Oncol Radiother 19:399–404. https://doi.org/10.1016/j.rpor.2014.04.005CrossRefPubMedPubMedCentral

33.

Pinzi V, Landoni V, Cattani F, Lazzari R, Jereczek-Fossa BA, Orecchia R (2019) IMRT and brachytherapy comparison in gynaecological cancer treatment: thinking over dosimetry and radiobiology. ecancer 13:993. https://doi.org/10.3332/ecancer.2019.993CrossRef

34.

Wali L, Helal A, Darwesh R, Attar M (2019) A dosimetric comparison of volumetric modulated arc therapy (VMAT) and high dose rate (HDR) brachytherapy in localized cervical cancer radiotherapy. J Xray Sci Technol 27:473–483. https://doi.org/10.3233/XST-180468CrossRefPubMed

35.

Jones R, Chen Q, Best R, Libby B, Crandley EF, Showalter TN (2014) Dosimetric feasibility of stereotactic body radiation therapy as an alternative to brachytherapy for definitive treatment of medically inoperable early stage endometrial cancer. Radiat Oncol 9:164. https://doi.org/10.1186/1748-717X-9-164CrossRefPubMedPubMedCentral

36.

Kauffmann G, Wu T, Al-Hallaq H, Hasan Y (2017) Triple-tandem high-dose-rate brachytherapy for early-stage medically inoperable endometrial cancer: initial report on acute toxicity and dosimetric comparison to stereotactic body radiation therapy. Brachytherapy 16:141–146. https://doi.org/10.1016/j.brachy.2016.10.004CrossRefPubMed

37.

Cilla S, Macchia G, Mattiucci G, Ianiro A, Romano C, Buwenge M et al (2020) Optimized stereotactic volumetric modulated arc therapy as an alternative to brachytherapy for vaginal cuff boost. A dosimetric study. Med Dosim 45:352–358. https://doi.org/10.1016/j.meddos.2020.05.003CrossRefPubMed

38.

Aydogan B, Mundt AJ, Smith BD, Mell LK, Wang S, Sutton H, Roeske JC (2006) A dosimetric analysis of intensity-modulated radiation therapy (IMRT) as an alternative to adjuvant high-dose-rate (HDR) brachytherapy in early endometrial cancer patients. Int J Radiat Oncol Biol Phys 65:266–273. https://doi.org/10.1016/j.ijrobp.2006.07.016CrossRefPubMed

39.

Yildrim BA, Dolek Y, Guler OC, Arslan G, Onal C (2019) Dosimetric comparison of vaginal vault brachytherapy vs applicator-guided stereotactic body radiotherapy with volumetric modulated arc therapy and helical tomotherapy for endometrium cancer patients. Med Dosim 44:332–338. https://doi.org/10.1016/j.meddos.2018.11.005CrossRef

40.

Pedicini P, Caivano R, Fiorentino A, Strigari L, Califano G, Barbieri V et al (2012) Comparative dosimetric and radiobiological assessment among a nonstandard RapidArc, standard RapidArc, classical intensity-modulated radiotherapy, and 3D brachytherapy for the treatment of the vaginal vault in patients affected by gynecologic cancer. Med Dosim 37:347–352. https://doi.org/10.1016/j.meddos.2011.11.009CrossRefPubMed

41.

Akiyama H, Pesznyák C, Béla D, Ferenczi Ö, Major T, Polgár C et al (2018) Image guided high-dose-rate brachytherapy versus volumetric modulated arc therapy for head and neck cancer: a comparative analysis of dosimetry for target volume and organs at risk. Radiol Oncol 52:461–467. https://doi.org/10.2478/raon-2018-0042CrossRefPubMedPubMedCentral

42.

Pennington JD, Park SJ, Abgaryan N, Banerjee R, Lee PP, Loh C et al (2015) Dosimetric comparison of brachyablation and stereotactic ablative body radiotherapy in the treatment of liver metastasis. Brachytherapy 14:537–542. https://doi.org/10.1016/j.brachy.2015.04.002CrossRefPubMed

43.

Hass P, Mohnike K, Kropf S, Brunner TB, Walke M, Albers D et al (2019) Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. Brachytherapy 18:823–828. https://doi.org/10.1016/j.brachy.2019.08.003CrossRefPubMed

44.

Walter F, Nierer L, Rottler M, Duque AS, Weingandt H, Well J (2021) Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma. Radiat Oncol 16:86. https://doi.org/10.1186/s13014-021-01812-7CrossRefPubMedPubMedCentral

45.

Chan MKH, Lee VWY, Kadoya N, Chiang CL, Wong MYP, Leung RWK et al (2018) Single fraction computed tomography-guided high-dose-rate brachytherapy or stereotactic body radiotherapy for primary and metastatic lung tumors? J Contemp Brachytherapy 10:446–453. https://doi.org/10.5114/jcb.2018.79335CrossRefPubMedPubMedCentral

46.

Hsu IC, Pickett B, Shinohara K, Krieg R, Roach M 3rd, Phillips T (2000) Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation. Int J Radiat Oncol Biol Phys 46:851–858. https://doi.org/10.1016/s0360-3016(99)00501-5CrossRefPubMed

47.

Fuller DB, Naitoh J, Lee C, Hardy S, Jin H (2008) Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70:1588–1597. https://doi.org/10.1016/j.ijrobp.2007.11.067CrossRefPubMed

48.

Hermesse J, Biver S, Jansen N, Lenaerts E, De Patoul N, Vynckier S et al (2009) A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy. Strahlenther Onkol 185:736–742. https://doi.org/10.1007/s00066-009-2009-5CrossRefPubMed

49.

Hermesse J, Biver S, Jansen N, Lenaerts E, Nickers P (2010) Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate. Int J Radiat Oncol Biol Phys 76:269–276. https://doi.org/10.1016/j.ijrobp.2009.05.046CrossRefPubMed

50.

Murali V, Kurup PGG, Mahadev P, Mahalakshmi S (2010) Dosimetric analysis and comparison of IMRT and HDR brachytherapy in treatment of localized prostate cancer. J Med Phys 35:113–119. https://doi.org/10.4103/0971-6203.62201CrossRefPubMedPubMedCentral

51.

Sudahar H, Phil M, Kurup PGG, Murali V, Mahadev P, Velmurugan J (2013) Analysis of high-dose rate brachytherapy dose distribution resemblance in CyberKnife hypofractionated treatment plans of localized prostate cancer. Med Dosim 38:385–389. https://doi.org/10.1016/j.meddos.2013.04.006CrossRefPubMed

52.

Spratt DE, Scala LM, Folkert M, Voros L, Cohen GN, Happersett L et al (2013) A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. Brachytherapy 12:428–433. https://doi.org/10.1016/j.brachy.2013.03.003CrossRefPubMed

53.

Georg D, Hopfgartner J, Gora J, Kuess P, Kragl G, Berger D et al (2014) Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 88:715–722. https://doi.org/10.1016/j.ijrobp.2008.03.032CrossRefPubMed

54.

Fukuda S, Seo Y, Shiomi H, Yamada Y, Ogata T, Morimoto M et al (2014) Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife. J Radiat Res 55:1114–1121. https://doi.org/10.1093/jrr/rru048CrossRefPubMedPubMedCentral

55.

Andrzejewski P, Kuess P, Knausl B, Pinker K, Georg P, Knoth J et al (2015) Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy. Radiother Oncol 117:509–514. https://doi.org/10.1016/j.radonc.2015.07.028CrossRefPubMed

56.

Yang R, Zhao N, Liao A, Wang H, Qu A (2016) Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer. Med Dosim 41:236–241. https://doi.org/10.1016/j.meddos.2016.06.002CrossRefPubMed

57.

Eade T, Hruby G, Booth J, Bromley R, Guo L, O’Toole A et al (2019) Results of a prospective dose escalation study of linear acceleratore based virtual brachytherapy (BOOSTER) for prostate cancer; virtual HDR brachytherapy for prostate cancer. Adv Radiat Oncol 4:623–630. https://doi.org/10.1016/j.adro.2019.03.015CrossRefPubMedPubMedCentral

58.

Sanmamed N, Lee J, Berlin A, Craig T, Lao B, Rink A et al (2020) Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: dosimetry, toxicity and health related quality of life. Radiother Oncol 149:240–245. https://doi.org/10.1016/j.radonc.2020.05.029CrossRefPubMed

59.

Chatzikonstantinou G, Keller C, Scherf C, Bathen B, Köhn J, Tselis N (2021) Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer. Brachytherapy 20:44–49. https://doi.org/10.1016/j.brachy.2020.07.011CrossRefPubMed

60.

Fröhlich G, Ágoston P, Jorgo K, Stelczer G, Polgár C, Major T (2021) Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer. Rep Pract Oncol Radiother 26:196–202. https://doi.org/10.5603/RPOR.a2021.0028CrossRefPubMedPubMedCentral

61.

Willigenburg T, Beld E, Hes J, Lagendijk JJW, de Boer HCJ, Moerland MA et al (2020) Focal salvage treatment for radiorecurrent prostate cancer: a magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study. Phys Imaging Radiat Oncol 15:60–65. https://doi.org/10.1016/j.phro.2020.07.006CrossRefPubMedPubMedCentral

62.

Park JM, Kim IH, Ye SJ, Kim K (2014) Evaluation of treatment plans using various treatment techniques for the radiotherapy of cutaneous Kaposi’s sarcoma developed on the skin of feet. J Appl Clin Med Phys 15:173–187. https://doi.org/10.1120/jacmp.v15i6.4970CrossRefPubMedCentral

63.

Boman EL, Paterson DB, Pearson S, Naidoo N, Johnson C (2018) Dosimetric comparison of surface mould HDR brachytherapy with VMAT. J Med Radiat Sci 65:311–318. https://doi.org/10.1002/jmrs.301CrossRefPubMedPubMedCentral

64.

Sen S, Bandyopadhyay A, Pal JK, Ghosh AK, Deb AR (2019) A dosimetric study of electron beam therapy vs. high-dose-rate mould brachytherapy in adjuvant treatment of non-melanoma skin carcinomas of the head and neck region. J Contemp Brachytherapy 11:547–553. https://doi.org/10.5114/jcb.2019.90233CrossRefPubMedPubMedCentral

65.

Mitra D, Pei Y, Buzurovic I, Devlin PM, Thornton K, Raut CP, Baldini EH, Lam MB (2020) Angiosarcoma of the scalp and face: a dosimetric comparison of HDR surface applicator brachytherapy and VMAT. Sarcoma 2020:7615248. https://doi.org/10.1155/2020/7615248CrossRefPubMedPubMedCentral

66.

Wills RJ, Lowe G, Jones CL, Hoskin PJ (2021) Dosimetric comparison of volumetric modulated arc therapy (VMAT) and high-dose-rate brachytherapy (HDR-BT) for superficial skin irradiation with significant curvature in one or more planes. Strahlenther Onkol. https://doi.org/10.1007/s00066-021-01759-4CrossRefPubMed

67.

Buzurovic IM, O’Farrell DA, Harris TC, Friesen S, King MT, Cormack RA et al (2021) Selection criteria for high-dose-rate surface brachytherapy and electron beam therapy in cutaneous oncology. J Contemp Brachytherapy 13:195–204. https://doi.org/10.5114/jcb.2021.105288CrossRefPubMedPubMedCentral

68.

Schefter TE, Kavanagh BD, Wu Q, Tong S, Newman F, McCourt S (2002) Technical considerations in the application of intensity-modulated radiotherapy as a concomitant integrated boost for locally-advanced cervix cancer. Med Dosim 27:177–184. https://doi.org/10.1016/S0958-3947(02)00101-2CrossRefPubMed

69.

Malhotra HK, Avadhani JS, de Boer SF, Jaggernauth W, Kuettel MR, Podgorsak MB (2007) Duplicating a tandem and ovoids distribution with IMRT: a feasibility study. J Appl Clin Med Phys 8:91–98. https://doi.org/10.1120/jacmp.v8i3.2450CrossRefPubMedPubMedCentral

70.

Milosević NT, Dabić-Stanković KM, Stanković JB, Mileusnić DS (2009) Conventional conformal radiotherapy vs intracavitary brachytherapy for the adjuvant postoperative treatment of cervical cancer: a comparative dosimetric study. Acta Chir Iugosl 56:189–194. https://doi.org/10.2298/ACI0904189MCrossRefPubMed

71.

Mollà M, Escude L, Nouet P, Popowski Y, Hidalgo A, Rouzaud M et al (2005) Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy? Int J Radiat Oncol Biol Phys 62:118–124. https://doi.org/10.1016/j.ijrobp.2004.09.028CrossRefPubMed

72.

Grelewicz Z, Zerrusen B, Sathiaseelan V, Zhang H (2017) A feasibility study of using advanced external beam techniques to create a vaginal cuff brachytherapy-like endometrial boost plan. Med Phys 44:1246–1256. https://doi.org/10.1002/mp.12165CrossRefPubMed

73.

Wojcicka JB, Lasher DE, McAfee SS, Fortier GA (2009) Dosimetric comparison of three different treatment techniques in extensive scalp lesion irradiation. Radiother Oncol 91:255–260. https://doi.org/10.1016/j.radonc.2008.09.022CrossRefPubMed

74.

Strnad V, Krug D, Sedlmayer F, Piroth MD, Budach W, Baumann R et al (2020) DEGRO practical guideline for partial-breast irradiation. Strahlenther Onkol 96:749–763. https://doi.org/10.1007/s00066-020-01613-zCrossRef

75.

Kindts I, Verhoeven K, Laenen A, Christiaens M, Janssen H, van der Vorst A et al (2019) A comparison of a brachytherapy and an external beam radiotherapy boost in breast-conserving therapy for breast cancer: local and any recurrences. Strahlenther Onkol 95:310–317. https://doi.org/10.1007/s00066-018-1413-0CrossRef

76.

Bodács I, Polgár C, Major T (2014) Dosimetric comparison of external partial breast irradiation with whole breast irradiation and partial breast brachytherapy. Magy Onkol 58:108–115PubMed

77.

Beaulieu L, Carlsson Tedgren Å, Carrier JF, Davis SD, Mourtada E et al (2012) Report of the task group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: current status and recommendations for clinical implementation. Med Phys 9:6208–6236. https://doi.org/10.1118/1.4747264CrossRef

78.

Videtic GMM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR et al (2015) NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase II study comparing 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 93:757–764. https://doi.org/10.1016/j.ijrobp.2015.07.2260CrossRefPubMedPubMedCentral

79.

Shi C, Guo B, Cheng CY, Esquivel C, Eng T, Papanikolaou N (2010) Three dimensional intensity modulated brachytherapy (IMBT): dosimetry algorithm and inverse treatment planning. Med Phys 37:3725–3737. https://doi.org/10.1118/1.3456598CrossRefPubMed

80.

Orio PF, Nguyen PL, Buzurovic I, Cail DW, Chen YW (2016) Prostate brachytherapy case volumes by academic and nonacademic practices: implications for future residency training. Int J Radiat Oncol Biol Phys 96:624–628. https://doi.org/10.1016/j.ijrobp.2016.07.013CrossRefPubMed

81.

Corey G, Yoosuf ABM, Workman G, Byrne M, Mitchell DM, Jain S (2018) UK & Ireland prostate brachytherapy practice survey 2014–2016. J Contemp Brachytherapy 10(3):238–245. https://doi.org/10.5114/jcb.2018.76839CrossRefPubMedPubMedCentral

82.

Kahn JM, Campbell SR, Albert AA, Knoll MA, Shah C (2021) ThisIsBrachytherapy: increasing awareness of brachytherapy. Brachytherapy 20:232–236. https://doi.org/10.1016/j.brachy.2020.07.003CrossRefPubMed

83.

Odei B, Bae S, Diaz DA (2021) Challenges influencing the utilization of prostate brachytherapy in the United States. Radiother Oncol 154:123–124. https://doi.org/10.1016/j.radonc.2020.09.025CrossRefPubMed

84.

Tagliaferri L, Vavassori A, Lancellotta V, De Sanctis V, Barbera F, Fusco V et al (2020) Can brachytherapy be properly considered in the clinical practice? Trilogy project: the vision of the AIRO (Italian association of radiotherapy and clinical oncology) Interventional radiotherapy study group. J Contemp Brachytherapy 12:84–89. https://doi.org/10.5114/jcb.2020.92765CrossRefPubMedPubMedCentral

85.

Donelly ED (2020) Adapting to ensure brachytherapy remains a vital component of our future. Brachytherapy 19:717. https://doi.org/10.1016/j.brachy.2020.09.008CrossRef

86.

Merrick GS (2020) The narrow door of success. Brachytherapy 19:1–5. https://doi.org/10.1016/j.brachy.2019.09.003CrossRefPubMed

87.

Cunha JAM, Flynn R, Bélanger C, Callaghan C, Kim Y, Jia X et al (2019) Brachytherapy future directions. Semin Radiat Oncol 30:94–106. https://doi.org/10.1016/j.semradonc.2019.09.001CrossRef

88.

Major T, Fröhlich G, Mészáros N, Smanykó V, Polgár C et al (2020) Does inverse planning improve the plan quality in interstitial high dose rate breast brachytherapy? J Contemp Brachytherapy 12:166–174. https://doi.org/10.5114/jcb.2020.94584CrossRefPubMedPubMedCentral

89.

Mohammadi R, Siavashpour Z, Aghdam SRH, Fazli S, Major T, Rohani AA (2021) Manufacturing and evaluation of multi-channel cylinder applicator with 3D printing technology. J Contemp Brachytherapy 13:80–90. https://doi.org/10.5114/jcb.2021.103590CrossRefPubMedPubMedCentral

Title: The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry
Authors: Tibor Major
Georgina Fröhlich
Péter Ágoston
Csaba Polgár
Zoltán Takácsi-Nagy
Publication date: 01-02-2022
Publisher: Springer Berlin Heidelberg
Keywords: Brachytherapy
Radiotherapy
Published in: Strahlentherapie und Onkologie / Issue 2/2022
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-021-01867-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Adjuvant chemoradiotherapy in elderly patients with head and neck cancer: a monoinstitutional, two-to-one pair-matching analysis

Dosiseskalation beim Prostatakarzinom: Standarddosis versus Dosiseskalation mit simultan integriertem Boost auf die intraprostatische Tumorformation: Ergebnisse der FLAME-Studie

Patterns of care analysis for salivary gland cancer: a survey within the German Society of Radiation Oncology (DEGRO) and recommendations for daily practice

Neoadjuvant chemoradiotherapy for locally advanced rectal cancer with peritumoral abscesses and fistulas

Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients

The impact of nutritional counseling on thyroid disorders in head and neck cancer patients after (chemo)radiotherapy: results from a prospective interventional trial